Enzymatic DNA Synthesis Market Size, Share, By Services (Oligonucleotide Synthesis, and Gene Synthesis), Application (Synthetic Biology, Genetic Engineering, Vaccine Development, and Others), End Use (Biopharmaceutical Companies, Academic & Research Institutes, and Others), and Region - Trends, Analysis, and Forecast till 2035

• Enzymatic DNA synthesis market size is expected to expand at a rate of USD 16.0 Billion, by 2035.
• In 2024, the Enzymatic DNA synthesis market valuation was USD 5.89 Billion.
• The Enzymatic DNA synthesis market is growing at a CAGR 10.6%.

Using enzymes (biological catalysts) instead of more conventional chemical techniques (such as phosphoramidite synthesis), enzymatic DNA synthesis is a contemporary technique for producing synthetic DNA. Compared to conventional chemical techniques, enzymatic DNA synthesis has a number of important advantages. As it uses fewer harmful chemicals and generates less trash, it is more environmentally friendly. The method makes it possible to synthesize DNA more quickly and precisely, producing longer sequences with more fidelity. This makes it perfect for cutting-edge uses in gene therapy, customized medicine, and synthetic biology.

The enzymatic DNA synthesis market has grown significantly as a result of multiple concurrent causes. The need for accurate and effective DNA synthesis techniques has increased due to developments in synthetic biology and gene editing technologies notably CRISPR-Cas9. The increasing focus on personalized medicine, where customized DNA sequences are crucial for creating customized treatments, raises this demand. Furthermore, the growing field of genetic research and diagnostics demands precise and quick DNA synthesis, making enzymatic techniques a desirable substitute for conventional chemical synthesis due to their affordability and speed. The market is expanding as a result of the rising incidence of chronic illnesses and the search for cutting-edge treatment options includes gene therapy.

Multiple new prospects are driving the market for enzymatic DNA synthesis, which is expected to increase significantly. Combining CRISPR-Cas9 technology is improving genetic manipulation accuracy and increasing the use of gene editing and synthetic biology. Automation and robotics developments are increasing productivity and throughput, allowing for the quick and large-scale customization of DNA structures. The creation of new DNA polymerases with improved fidelity is making it easier to synthesize longer and more intricate DNA sequences, expanding the field of study and potential medical uses.

Impact of Generative AI on Enzymatic DNA Synthesis Market:

• By improving the design and optimization of DNA sequences, generative AI is having a major impact on the market for enzymatic DNA synthesis. Advanced AI models, such as Yale's CODA platform, may construct unique regulatory DNA elements that accurately control gene expression, a capacity critical for targeted gene therapies.
• Additionally, AI-powered technologies are advancing enzyme engineering, making it possible to create enzymes for DNA synthesis processes that are more effective. These developments are speeding up research and development, cutting expenses, and increasing the range of possible uses for enzymatic DNA synthesis in synthetic biology, biotechnology, and customized medicine.

Key Drivers:

The Rising Incidence of Chronic Diseases Encourages the Market

The enzymatic DNA synthesis market is growing due in large part to the increased prevalence of chronic illnesses including cancer, hereditary disorders, and cardiovascular conditions. These disorders frequently call for sophisticated diagnostic instruments and individualized therapeutic strategies, both of which depend on accurate and effective DNA synthesis. Enzymatic DNA synthesis makes it possible to produce tailored DNA sequences quickly and accurately, which is crucial for the development of targeted medications, gene treatments, and molecular diagnostics. The need for novel and scalable DNA synthesis technologies is anticipated to increase as healthcare systems move more and more toward precision medicine to better manage chronic illnesses, which will drive market growth.

• For Instance, according to the data published by National Library of Medicine, each year 18 million people die from cardiovascular diseases that affect the heart and blood vessels and can lead to heart attacks, stroke, or heart failure. About 9 million people die each year from cancers, 4 million from chronic respiratory diseases such as asthma or COPD, and 2 million from diabetes.

Restraints:

The Market's Development might be inhibited by the Limited Synthesis Length

The inability of enzymatic DNA synthesis to accurately produce lengthy DNA sequences is one of its main drawbacks. Enzymatic procedures frequently encounter difficulties including premature termination, misincorporation of bases, or structural instability of larger chains, in contrast to conventional chemical methods that can consistently manufacture longer strands through stepwise nucleotide addition. This limits their use in big gene constructs or intricate genome assembly.

• Counterbalance Statements: In order to get around this, scientists are working on creating hybrid strategies that blend enzymatic and chemical synthesis techniques, as well as constructing more accurate and efficient DNA polymerases. By extending the synthesis length while preserving high fidelity, these developments hope to increase the viability of enzymatic DNA synthesis for use in advanced genetic engineering and medicinal applications.

Opportunities & Trends:

The Future of Targeted Market is Booming due to the Multiple New Prospects

The enzymatic DNA synthesis market is expanding with a number of intriguing new prospects. Fast, precise, and scalable DNA synthesis is becoming more and more necessary as industries including gene editing, synthetic biology, and customized medicine develop quickly. New uses for synthetic DNA are opening up new sectors, including biosensor development, vaccine manufacturing, DNA-based data storage, and sustainable agriculture. Furthermore, enzymatic synthesis is becoming more accessible and effective because to developments in automation, enzyme engineering, and artificial intelligence. It is anticipated that these developments, along with rising biotechnology investment worldwide, will open up new applications and promote broad acceptance, establishing enzymatic DNA synthesis as a fundamental component of the next generation of life sciences.

The Enzymatic DNA Synthesis Market is segmented into services, application, end use, and region.

By Services:

The Enzymatic DNA synthesis market is segmented by services, including oligonucleotide synthesis, and gene synthesis. In light of their broad operational use, lower development complexity, and demonstrated durability, Oligonucleotide Synthesis now have the largest enzymatic DNA synthesis market share.

The highest share is held by oligonucleotide synthesis owing to its numerous uses in research, medicine, and diagnostics. Demand has increased dramatically as oligonucleotides are increasingly used in PCR-based diagnostic assays, particularly in the wake of the COVID-19 epidemic. Their increasing involvement in RNA-based medications, antisense medicines, and gene editing technologies including CRISPR has further increased their market share.

By Application:

According to the application, the enzymatic DNA synthesis market is categorized into synthetic biology, genetic engineering, vaccine development, and others. Among applications, synthetic biology has the highest enzymatic DNA synthesis market share because of its widespread and quickly growing use in a variety of sectors, including environmental biotechnology, medicines, and agriculture.

The second most popular category is genetic engineering, which includes a variety of uses such as crop modification, gene editing, and the creation of gene-based medicines.

By End Use:

Biopharmaceutical companies, academic & research institutes, and others are the end use of the Enzymatic DNA Synthesis Market. Since biopharmaceutical companies have a significant need for quick, precise, and scalable DNA synthesis for gene therapy, drug discovery, vaccine research, and biologics manufacturing, they have the highest share of end users.

The second-biggest category is made up of academic and scientific institutions, which are distinguished by their emphasis on basic research, genome studies, and advancements in biotechnology.

Regional Insights:

Geographically, the Enzymatic DNA Synthesis Market is studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America: Enzymatic DNA synthesis market was dominated by the North America region. The main causes of this dominance are the large number of top pharmaceutical and biotechnology firms, sophisticated research facilities, and large expenditures in genetic engineering and synthetic biology.

• U.S. Enzymatic DNA Synthesis Market Insights:

The enzymatic DNA synthesis market is largely controlled by the U.S. Its strong biotechnology and pharmaceutical sectors, considerable government and private sector investments in genetic research, and the existence of prominent players in the DNA synthesis market are all big contributors to this.

Asia Pacific:

With significant expenditures in biotechnology and life sciences in nations including China, India, Japan, and South Korea, the Asia Pacific region is the one with the fastest-growing enzymatic DNA synthesis market. The need for accurate DNA synthesis methods is rising as a result of these countries' aggressive expansion of their genomics, personalized medicine, and genetic engineering research and development initiatives.

• China Enzymatic DNA Synthesis Market Insights:

The enzymatic DNA synthesis market is dominated by China. China's substantial investments in biotechnology and life sciences, solid infrastructure for research and development, and the presence of important industry players are all factors in this leadership.

Europe: The enzymatic DNA synthesis market in Europe is expanding significantly due to a number of important factors. First off, the increasing number of genetic illnesses has increased the need for individualized therapy and sophisticated genetic testing, which calls for accurate and effective DNA synthesis technology. Second, significant investments in R&D by both public and private organizations have resulted in the introduction of novel devices that simplify molecular biology operations, such as benchtop DNA synthesizers.

• Germany Enzymatic DNA Synthesis Market Insights:

The European enzymatic DNA synthesis market is presently dominated by Germany. This dominance is ascribed to Germany's strong pharmaceutical and biotechnology industries, large R&D expenditures, and the existence of important industry participants. Strong academic and scientific institutions in the nation, along with encouraging government programs, have created an atmosphere that is favorable to developments in genetic engineering and synthetic biology, which has further fueled the expansion of the EDS market.

Enzymatic DNA Synthesis Market Report Scope:

Attribute	Details
Market Size 2025	USD 6.4 Billion
Projected Market Size 2035	USD 16.0 Billion
CAGR Growth Rate	10.6% (2025-2035)
Base year for estimation	2024
Forecast period	2025 – 2035
Market representation	Revenue in USD Billion & CAGR from 2025 to 2035
Regional scope	North America - U.S. and Canada Europe – Germany, U.K., France, Russia, Italy, Spain, Netherlands, and Rest of Europe Asia Pacific – China, India, Japan, Australia, Indonesia, Malaysia, South Korea, and Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, and Rest of Latin America Middle East & Africa – GCC, Israel, South Africa, and Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segmentation:

By Services:

• Oligonucleotide Synthesis
• Gene Synthesis

By Application:

• Synthetic Biology
• Genetic Engineering
• Vaccine Development
• Others

By End Use:

• Biopharmaceutical Companies
• Academic & Research Institutes
• Others

By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Russia
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • Indonesia
  • Malaysia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Among the leading companies in the market for enzymatic DNA synthesis market are Evonetix, DNA TwoPointO, Inc., GenScript, TELESIS BIO INC., DNA Script, and others. One of the main tactics propelling the enzymatic DNA synthesis (EDS) market's expansion is the establishment of strategic alliances and partnerships with biotech firms, educational institutions, and research groups in order to boost innovation and broaden application areas.

Enzymatic DNA Synthesis Market Companies:

• Telesis Bio Inc.
• Evonetix
• Ansa Biotechnologies
• Camena Bioscience
• GenScript
• DNA Script
• Eurofins Scientific
• Synbio Technologies
• DNA TwoPointO, Inc.
• Twist Bioscience
• Elegen Corporation
• Yeasen
• Molecular Assemblies
• GenomeWeb

View an Additional List of Companies in the Enzymatic DNA Synthesis Market

• In May 2025, in order to sell shares of a new series of convertible preferred stock in a private placement, Telesis Bio stated that it has signed a convertible preferred stock purchase agreement (the Purchase Agreement).  Customers can take complete control of their nucleic acid supply chain, safeguard important intellectual property, and keep ownership of data and insights to feed future generations of AI drug discovery models using the companies newly released patented next-generation enzymatic synthesis platform, Gibson SOLA. Customers may use standard automated liquid handling equipment to undertake overnight synthesis of long, complicated complexes required for research and development of biologics, vaccines, and cell therapies thanks to the Gibson SOLA reagent platform and full suite of software.
• In May 2024, A pioneer and leader in the field of enzymatic DNA synthesis, Molecular Assemblies, Inc., announced the opening of its Partnering Program to license its Fully Enzymatic SynthesisTM (FESTM) technology for on-site synthesis. In order to power a new, quickly developing generation of treatments and diagnostics, FES technology speeds up the manufacture of lengthy, clean, and accurate DNA.
• In August 2022, A Commercial License and Enzyme Supply Agreement was recently executed by Molecular Assemblies, Inc., a pioneer in the field of enzymatic DNA synthesis, and Codexis, Inc., a leading enzyme engineering company that makes synthetic biology possible. This agreement allows Molecular Assemblies to use an evolved terminal deoxynucleotidyl transferase (TdT) enzyme in their Fully Enzymatic SynthesisTM (or FESTM) technology. Together, the businesses created an enhanced TdT enzyme to promote fully enzymatic DNA synthesis and produce long, precise, and pure oligonucleotides, which will spur innovation across numerous industries.

Analyst View:

Due to several factors, the market for enzymatic DNA synthesis has expanded dramatically. Advances in synthetic biology and gene editing tools, particularly CRISPR-Cas9, have raised the demand for precise and efficient DNA synthesis methods. This need is heightened by the growing emphasis on personalized medicine, where unique DNA sequences are essential for developing tailored therapies. Furthermore, due to their speed and affordability, enzymatic approaches are an attractive alternative to conventional chemical synthesis in the expanding fields of genetic research and diagnostics, which require precise and rapid DNA synthesis. The growing prevalence of chronic illnesses and the need for innovative treatment alternatives, such as gene therapy, are driving the market's expansion.

More Related Reports

Enzymatic Debridement Market
Recombinant DNA technology Market
T4 DNA Ligase Market
DNA Sequencing Market
DNA Synthesis Market

Company Name	MOLECULAR ASSEMBLIES
Headquarter	Luxembourg
CEO	Dr. Gilles Martin
Employee Count	63,000 Employees